Rani Therapeutics (RANI) Competitors $1.40 +0.10 (+7.69%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RANI vs. CYRX, DSGN, PROC, BTMD, NGNE, VYGR, CTNM, SLRN, KMDA, and TRVIShould you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Cryoport (CYRX), Design Therapeutics (DSGN), Procaps Group (PROC), biote (BTMD), Neurogene (NGNE), Voyager Therapeutics (VYGR), Contineum Therapeutics (CTNM), Acelyrin (SLRN), Kamada (KMDA), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry. Rani Therapeutics vs. Cryoport Design Therapeutics Procaps Group biote Neurogene Voyager Therapeutics Contineum Therapeutics Acelyrin Kamada Trevi Therapeutics Cryoport (NASDAQ:CYRX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap transportation companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations. Do insiders and institutionals hold more shares of CYRX or RANI? 92.9% of Cryoport shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 10.1% of Cryoport shares are owned by company insiders. Comparatively, 53.3% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in CYRX or RANI? Cryoport received 211 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 81.58% of users gave Rani Therapeutics an outperform vote while only 65.05% of users gave Cryoport an outperform vote. CompanyUnderperformOutperformCryoportOutperform Votes24265.05% Underperform Votes13034.95% Rani TherapeuticsOutperform Votes3181.58% Underperform Votes718.42% Is CYRX or RANI more profitable? Rani Therapeutics has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Cryoport's return on equity of -13.35% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cryoport-70.08% -13.35% -6.43% Rani Therapeutics N/A -219.64%-56.71% Which has higher valuation and earnings, CYRX or RANI? Rani Therapeutics has lower revenue, but higher earnings than Cryoport. Cryoport is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoport$226.11M1.72-$99.59M-$3.38-2.33Rani Therapeutics$2.72M29.49-$33.97M-$1.06-1.32 Does the media favor CYRX or RANI? In the previous week, Rani Therapeutics had 1 more articles in the media than Cryoport. MarketBeat recorded 4 mentions for Rani Therapeutics and 3 mentions for Cryoport. Rani Therapeutics' average media sentiment score of 1.43 beat Cryoport's score of 0.97 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cryoport 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, CYRX or RANI? Cryoport has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Do analysts rate CYRX or RANI? Cryoport currently has a consensus target price of $12.29, suggesting a potential upside of 56.31%. Rani Therapeutics has a consensus target price of $11.71, suggesting a potential upside of 736.73%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cryoport 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryRani Therapeutics beats Cryoport on 13 of the 19 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RANI vs. The Competition Export to ExcelMetricRani TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.21M$6.57B$5.01B$9.08BDividend YieldN/A3.09%4.87%4.21%P/E Ratio-1.3210.55135.0717.15Price / Sales29.49195.041,120.63116.80Price / CashN/A57.1640.5837.88Price / Book2.755.104.754.78Net Income-$33.97M$151.51M$118.50M$225.60M7 Day Performance-15.66%-2.13%-1.85%-1.21%1 Month Performance-31.03%-3.13%11.28%3.09%1 Year Performance-55.41%11.54%29.92%16.48% Rani Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RANIRani Therapeutics3.4495 of 5 stars$1.40+7.7%$11.71+736.7%-55.1%$80.21M$2.72M-1.32110Positive NewsCYRXCryoport3.0208 of 5 stars$7.53-2.1%$12.50+66.0%-49.8%$372.22M$226.11M-2.321,170Analyst ForecastGap DownDSGNDesign Therapeutics0.926 of 5 stars$6.43+14.8%$7.00+8.9%+143.2%$364.07MN/A-7.1840News CoveragePositive NewsPROCProcaps Group0.9123 of 5 stars$3.21+33.2%N/A-20.3%$362.15M$414.10M5.105,500News CoverageGap UpHigh Trading VolumeBTMDbiote3.2421 of 5 stars$6.60+3.6%$9.11+38.0%+20.8%$358.62M$193.06M24.77194Positive NewsGap UpNGNENeurogene3.7244 of 5 stars$24.03+2.2%$60.83+153.2%N/A$356.97M$925,000.000.0090VYGRVoyager Therapeutics4.6047 of 5 stars$6.50+3.7%$17.00+161.5%-27.6%$355.10M$250.01M8.83100CTNMContineum Therapeutics1.9464 of 5 stars$13.56-3.3%$29.25+115.7%N/A$349.58M$50M0.0031News CoverageSLRNAcelyrin2.5887 of 5 stars$3.42+5.9%$11.75+243.6%-55.8%$343.13MN/A-1.31135KMDAKamada3.8898 of 5 stars$5.84-0.5%$14.50+148.3%-1.2%$335.68M$158.38M20.96360Positive NewsTRVITrevi Therapeutics3.0381 of 5 stars$4.34+4.1%$9.31+114.6%+214.0%$333.62MN/A-10.2020Gap DownHigh Trading Volume Related Companies and Tools Related Companies CYRX Alternatives DSGN Alternatives PROC Alternatives BTMD Alternatives NGNE Alternatives VYGR Alternatives CTNM Alternatives SLRN Alternatives KMDA Alternatives TRVI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RANI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RANI Stock Alerts